A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma.

Trial Profile

A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PROPEL
  • Sponsors Allos Therapeutics
  • Most Recent Events

    • 06 Dec 2016 Case match control analysis results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Results from a case match control analysis published in a Spectrum Pharmaceuticals Media Release.
    • 06 Dec 2016 Data from a case match control analysis of this study presented at the 58th American Society of Hematology (ASH) Annual Meeting 2016, according to a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top